Mechanism of Action of Pseudomonas Exotoxin. Identification of a Rate-limiting Step
Overview
Authors
Affiliations
Pseudomonas exotoxin (PE) enters cells by receptor-mediated endocytosis and is cleaved by a cellular protease between Arg279 and Gly280 to produce an NH2-terminal fragment of 28 kDa which contains the toxin's binding domain and a COOH-terminal fragment of 37 kDa which has translocating and ADP-ribosylating activity. After proteolysis, the COOH-terminal fragment reaches the endoplasmic reticulum by retrograde transport where it translocates to the cytosol and inhibits protein synthesis by ADP-ribosylating elongation factor 2. To understand how the 37-kDa fragment functions, we focused on the role of specific amino acids located near its NH2 terminus. We found that there was a 4-250-fold loss in toxic activity when tryptophan 281, leucine 284, or tyrosine 289 were changed to other residues. Mutations at these three positions did not interfere with the receptor binding, cell-mediated proteolytic cleavage, or ADP-ribosylating activity. To determine the role of these amino acids, a competition assay was devised in which the addition of excess PE delta 553, a mutant form of PE that lacks ADP-ribosylation activity, competed efficiently for the toxicity of PE. Excess PE with mutations near the NH2 terminus of the 37-kDa fragment competed poorly. This competition occurred after proteolysis since PEGly276, a mutant form of PE that is not cleaved, did not complete. We conclude that specific amino acids at the NH2 terminus of the 37-kDa fragment interact in a saturable manner with an unknown intracellular component.
Dicovitsky R, Schappa J, Schulte A, Lang H, Kuerbitz E, Roberts S Toxins (Basel). 2024; 16(9).
PMID: 39330834 PMC: 11436214. DOI: 10.3390/toxins16090376.
Triggered Exosomal Release of ADAM10 Mediates Proteolytic Cleavage in Trans.
Aljohmani A, Opitz B, Bischoff M, Yildiz D Int J Mol Sci. 2022; 23(3).
PMID: 35163191 PMC: 8835980. DOI: 10.3390/ijms23031259.
Metrangolo V, Ploug M, Engelholm L Cancers (Basel). 2021; 13(21).
PMID: 34771541 PMC: 8582577. DOI: 10.3390/cancers13215376.
Liu X, Li H, Cong X, Huo D, Cong L, Wu G Onco Targets Ther. 2020; 13:12457-12469.
PMID: 33299329 PMC: 7721307. DOI: 10.2147/OTT.S268554.
Fernandez-Bravo A, Kilgore P, Andersson J, Blears E, Figueras M, Hasan N Proc Natl Acad Sci U S A. 2019; 116(48):24084-24092.
PMID: 31712444 PMC: 6883842. DOI: 10.1073/pnas.1914395116.